GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » 3-Year Book Growth Rate

Agios Pharmaceuticals (Agios Pharmaceuticals) 3-Year Book Growth Rate : 36.00% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals 3-Year Book Growth Rate?

Agios Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $14.50.

During the past 12 months, Agios Pharmaceuticals's average Book Value per Share Growth Rate was -27.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was 36.00% per year. During the past 5 years, the average Book Value per Share Growth Rate was 14.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was 10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Agios Pharmaceuticals was 36.00% per year. The lowest was -12.40% per year. And the median was 17.60% per year.

Competitive Comparison of Agios Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Agios Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's 3-Year Book Growth Rate falls into.


Agios Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Agios Pharmaceuticals  (NAS:AGIO) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Agios Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals (Agios Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » 3-Year Book Growth Rate
Comparable Companies
RYZB ZNTL CVAC RXRX MNKD TGTX SAGE RCUS MRUS ABCL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AGIO:Mexico 8AP:Germany 8AP:Germany
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Website
https://www.agios.com
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Executives
Brian Goff director, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens officer: Chief Medical Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns officer: Chief Legal Officer C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Cecilia Jones officer: Chief Financial Officer C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Washburn Theodore James Jr. officer: Principal Accounting Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen director 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
David P Schenkein director, 10 percent owner, officer: Chief Executive Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rahul D. Ballal director 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Richa Poddar officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson officer: Principal Accounting Officer 88 SIDNEY STREET, CAMBRIDGE MA 02139